Semler Launches WellChec(TM) Platform
Share:
- Basic tests for diseases of the arteries, lungs, eyes, nerves and heart -
PORTLAND, Ore., -- Semler Scientific, Inc. (Nasdaq: SMLR), an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced the launch of its multi-test platform, WellChec(TM), to perform risk assessments for the healthcare insurance industry.
The catalyst for preventative medicine is to recognize disease processes early in their course and to institute care management to affect clinical outcomes. However the primary care physician shortage impedes efforts to make these early diagnoses and interventions. Cost effective wellness is desired by patients, the government, physicians and the insurance industry. Now, Semler's suite of services called WellChec(TM) is available to do basic tests for diseases of the arteries, lungs, eyes, nerves and heart.
"We believe the economy of scale to combine tests and services provides greater return on investment for our clients, enhanced revenue opportunity for us and may reduce overall healthcare expenditures for disease management. It is the intent of the service to both provide the equipment and tools to do the tests as well as personnel on a sub-contracted basis to perform the measurements," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler.
"Our target market is health insurance plans and integrated healthcare delivery systems who want to do health risk assessments and preventative care management. WellChec(TM) is intended to be a one-stop shopping solution where these customers can get the information that they need without burdening the primary care doctors who are in short supply," continued Dr. Murphy-Chutorian.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases. Semler's first patented and U.S. Food and Drug Administration cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. Additional information about Semler can be found at www.semlerscientific.com.
